Nordström Dan, Leirisalo-Repo Marjatta, Petterson Tom
HYKS, Sisätautien ja Reumatologian Klinikka Helingin Yliopisto, Klininen Laitos.
Duodecim. 2013;129(10):1045-8.
Biologic TNF alpha blocker medication was started for a patient having active rheumatoid arthritis, because the disease was unresponsive to conventional drugs and the patient also 'had reactive amyloidosis. Due to weakening efficiency and simultaneously occurring gout the medication was replaced by an IL-1 receptor blocker, which in addition to controlling rheumatoid arthritis also acts by suppressing gouty attacks. Finding an optimized drug combination for rheumatoid patients will become easier with the increasing number of biologic drugs functioning through different mechanisms of action.
对于一名患有活动性类风湿性关节炎的患者，开始使用生物肿瘤坏死因子α阻滞剂进行治疗，因为该疾病对传统药物无反应，且该患者还患有反应性淀粉样变性。由于疗效减弱以及同时出现痛风，该药物被白细胞介素-1受体阻滞剂所取代，后者除了控制类风湿性关节炎外，还通过抑制痛风发作起作用。随着越来越多通过不同作用机制发挥作用的生物药物的出现，为类风湿患者找到优化的药物组合将变得更加容易。
